Soluble powder for treating avian coccidiosis and preparation method thereof
Through the combination of sulfaclopyrazine sodium-β-cyclodextrin inclusion compound and L-menthol, the problem of sulfaclopyrazine sodium being easily decomposed under high temperature and high humidity environment was solved, significantly improving its stability and treatment It exhibits excellent efficacy during coccidiosis.
Patent Information
- Application Number
- CN202411175826.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Sodium sulfaclopyrazine is sensitive to light and is easy to decompose in high temperature and high humidity environments, resulting in a decrease in its stability. The prior art has failed to effectively solve this problem.
The sulfaclopyrazine sodium-β-cyclodextrin inclusion was used, and L-menthol was added as a stabilizer during the preparation process. The sulfaclopyrazine sodium was protected by inclusion technology, and combined with pharmaceutical excipients to improve stability and solubility. .
It significantly improved the stability of sulfaclopyrazine sodium and showed a slightly better therapeutic effect than commercially available preparations in the treatment of coccidiosis, overcoming the decomposition problems in light, high temperature and high humidity environments.
Smart Images

Figure CN118948775A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of veterinary drugs, and particularly relates to a soluble powder for treating avian coccidiosis and a preparation method thereof. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] Coccidiosis is an infectious disease caused by the protozoan Coccidia, which is mainly transmitted to humans and other mammals by certain types of mosquitoes that bite infected people. The disease is widely distributed around the world, especially in tropical and subtropical regions. There are several major types of coccidiosis, including the following: (1) Paracortical coccidiosis: This is the most common type of coccidiosis and usually causes skin lesions such as ulcers or nodules. Lesions can form on exposed areas such as the face, ears, and arms. (2) Mucosal coccidiosis: This type is more serious, and the coccidia infection can spread to the respiratory mucosa, causing severe tissue damage and ulcer formation, which may lead to permanent facial deformity. (3) Visceral coccidiosis, also known as Indian enuresis: This is the most serious type, and the coccidia invade the internal organs, especially the spleen, liver, and bone marrow, causing severe systemic infection. Visceral coccidiosis can be fatal if not treated. Symptoms of coccidiosis vary depending on the type of disease and the site of infection, and usually include skin lesions, ulcers, fever, anemia, and splenomegaly.
[0004] Sulfonamide chloropyrazine sodium is a sulfonamide drug used to treat coccidiosis, especially visceral coccidiosis. This drug is an antiprotozoal drug, and its mechanism of action is mainly to inhibit the growth and replication of coccidia to achieve the therapeutic effect. Sulfonamide chloropyrazine sodium is chemically named N-(5-chloro-3-pyrazinyl)-4-aminobenzenesulfonamide sodium salt monohydrate, with a molecular weight of 324.72 and a molecular formula of C 10 H8ClN4NaO2S·H2O, white or light yellow powder, odorless, soluble in water or methanol, slightly soluble in ethanol or acetone, insoluble in chloroform.
[0005] The Chinese patent with publication number CN105267148A discloses a soluble powder of sulfachloropyrazine sodium, which mainly includes the following components by weight: 10-30 parts of sulfachloropyrazine sodium, 2-5 parts of sodium carbonate, 0.1-0.5 parts of disodium ethylenediaminetetraacetate, and 70-85 parts of sucrose. Disodium ethylenediaminetetraacetate is used as a complexing agent and stabilizer to increase the stability of the drug, improve the solubility and bioavailability of sulfachloropyrazine sodium, and sodium carbonate can adjust the pH of the solution, provide an alkaline environment for sulfachloropyrazine sodium, and increase its solubility.
[0006] The Chinese patent with publication number CN106137973A discloses a compound sulfachloropyrazine sodium soluble powder. Each 100g of the soluble powder is made of the following components: 15-25g of sulfachloropyrazine sodium, 3-5g of a synergist, 40-60g of polyethylene glycol 6000, polyethylene glycol 4000 or a mixture of the two, 2-4g of polyvinyl pyrrolidone, 5-10g of maltodextrin, and the balance is anhydrous glucose; a dual water-soluble combined carrier material is used to increase the solubility and dissolution rate of the synergist through solid dispersion technology.
[0007] Sulfadiazine sodium is sensitive to light and will decompose when exposed to ultraviolet light. It should be avoided to store it in a bright environment. In addition, high temperature and high humidity environment may accelerate the decomposition and degradation of sulfadiazine sodium, especially under high temperature and high humidity conditions, the stability of the drug will be reduced. At present, the prior art does not solve the above problems. Summary of the invention
[0008] The invention overcomes the defects in the prior art that light, high temperature and high humidity environment can accelerate the decomposition and degradation of sulfachloropyrazine sodium and affect the stability of sulfachloropyrazine sodium, and provides a soluble powder for treating avian coccidiosis with high stability and good efficacy.
[0009] According to the structure of sulfachloropyrazine sodium ( Figure 1 ) analysis and judgment, the amino group in its structure is very easy to produce hydrogen bonds, suitable for combining with cyclic drug-carrying materials through intermolecular forces, so as to form inclusion compounds or supramolecular protection of sulfachloropyrazine sodium to prevent it from being affected by light, high temperature and high humidity. Based on the above design ideas, a sulfachloropyrazine sodium-β-cyclodextrin inclusion compound was designed and applied to sulfachloropyrazine sodium soluble powder.
[0010] The soluble powder consists of sulfachloropyrazine sodium-β-cyclodextrin inclusion compound and pharmaceutically acceptable auxiliary materials.
[0011] The sulfachloropyrazine sodium-β-cyclodextrin inclusion compound is composed of 1 to 3 parts by weight of sulfachloropyrazine sodium, 1 to 8 parts by weight of β-cyclodextrin, and 0.2 to 0.8 parts by weight of L-menthol.
[0012] The preparation method of sulfachloropyrazine sodium-β-cyclodextrin inclusion compound is as follows: (1) dissolving sulfachloropyrazine sodium in an appropriate amount of water to obtain a sulfachloropyrazine sodium aqueous solution, dissolving β-cyclodextrin in an appropriate amount of water to obtain a β-cyclodextrin aqueous solution, and dissolving L-menthol in an appropriate amount of ethanol to obtain an L-menthol solution, and set aside; (2) Place the β-cyclodextrin aqueous solution in a water bath at 35°C to 40°C and heat under reflux to remove some of the water. When the remaining liquid volume is 2 / 3 to 1 / 2 of the original volume, stop the operation and immediately transfer the solution to a beaker. Add the sodium sulfachloropyrazine aqueous solution dropwise along the wall of the beaker. After cooling, add the L-menthol solution dropwise to obtain a mixed solution. (3) The mixed solution is placed in a water bath at 30°C to 45°C for rotary evaporation until no distillate is produced. The precipitate is filtered, dried, and ground to obtain a sodium sulfachloropyrazine-β-cyclodextrin inclusion complex.
[0013] The addition of L-menthol improves the stability of sulfachloropyrazine sodium on the one hand, and on the other hand, due to its certain volatility, adding it at the right time can help remove the solvent and improve the yield.
[0014] Experiments have shown that the residual liquid volume in step (1) of heating under reflux in a water bath will affect the yield. Based on all the conditions in Example 1, the residual solution volume was changed to 4 / 5, and the yield of the sodium sulfachloropyrazine-β-cyclodextrin inclusion complex was 3.15 g.
[0015] It should be noted that the temperature range in the preparation method should be understood as starting heating from the low temperature and gradually increasing the temperature according to the amount of distillate or remaining solution, with the high temperature being the upper limit temperature.
[0016] The soluble powder is obtained by mixing the above-mentioned sodium sulfachloropyrazine-β-cyclodextrin inclusion compound with pharmaceutically acceptable excipients.
[0017] Further, the pharmaceutically acceptable excipients are selected from one or more of fillers, flavoring agents, lubricants, preservatives, and antioxidants. The fillers are selected from one or more of mannitol, microcrystalline cellulose, glucose, and lactose. The flavoring agents are selected from one or more of fructose, aspartame, glucose, and sucralose. The lubricants are selected from one or more of silicon dioxide, talcum powder, and magnesium stearate. The preservatives are selected from one or more of sodium benzoate, parabens, and potassium sorbate. The antioxidants are selected from one or more of sodium thiosulfate, sodium pyrosulfite, and ascorbic acid. The excipients are all commonly used excipients in the field of veterinary medicine, and their dosages are all pharmaceutically acceptable dosages, and the excipients will not have a significant impact on the present invention.
[0018] In addition, the present invention also provides the use of the soluble powder in preparing a medicine for treating avian coccidiosis.
[0019] Compared with the prior art, the technical effects of the present invention are: The present invention utilizes cyclodextrin inclusion technology to include sodium sulfachloropyrazine, and further preferably uses L-menthol as a stabilizer, thereby overcoming the defect that sodium sulfachloropyrazine is easily decomposed when exposed to light, high temperature and high humidity, and significantly improving the stability of sodium sulfachloropyrazine. In addition, the therapeutic effect of sodium sulfachloropyrazine soluble powder on chicken coccidiosis is also verified, and the therapeutic effect is slightly better than that of commercially available preparations. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 : Molecular structure of sulfachloropyrazine sodium.
[0021] Figure 2 : Appearance diagram of sulfachloropyrazine sodium-β-cyclodextrin inclusion complex of Example 1.
[0022] Figure 3 : Changes in the sodium sulfachloropyrazine content in the accelerated test of the sodium sulfachloropyrazine-β-cyclodextrin inclusion complexes of Examples 1 to 3 and Comparative Examples 1 to 4. DETAILED DESCRIPTION
[0023] In order to make the purpose and technical solution of the present invention clearer, the present invention is further described below in conjunction with embodiments, but the protection scope of the present invention is not limited to these embodiments, and the embodiments are only used to explain the present invention. It should be understood by those skilled in the art that any changes or equivalent substitutions that do not deviate from the concept of the present invention are included in the protection scope of the present invention.
[0024] Example 1 Sulfadiazine sodium-β-cyclodextrin inclusion complex formula: Preparation method: (1) dissolving sulfachloropyrazine sodium in an appropriate amount of water to obtain a sulfachloropyrazine sodium aqueous solution, dissolving β-cyclodextrin in an appropriate amount of water to obtain a β-cyclodextrin aqueous solution, and dissolving L-menthol in an appropriate amount of ethanol to obtain an L-menthol solution, and set aside; (2) Place the β-cyclodextrin aqueous solution in a water bath at 35°C to 40°C and heat under reflux to remove some of the water. When the remaining liquid volume is 1 / 2 of the original volume, stop the operation and immediately transfer it to a beaker. Add the sodium sulfachloropyrazine aqueous solution dropwise along the wall of the beaker. After cooling, add the L-menthol solution dropwise to obtain a mixed solution. (3) The mixed solution was placed in a water bath at 30°C to 45°C and subjected to rotary evaporation until no distillate was produced. The precipitate was filtered, dried, and ground to obtain 4.02 g of sodium sulfachloropyrazine-β-cyclodextrin inclusion complex.
[0025] Example 2 Sulfadiazine sodium-β-cyclodextrin inclusion complex formula: Preparation method: (1) dissolving sulfachloropyrazine sodium in an appropriate amount of water to obtain a sulfachloropyrazine sodium aqueous solution, dissolving β-cyclodextrin in an appropriate amount of water to obtain a β-cyclodextrin aqueous solution, and dissolving L-menthol in an appropriate amount of ethanol to obtain an L-menthol solution, and set aside; (2) Place the β-cyclodextrin aqueous solution in a water bath at 35°C to 40°C and heat under reflux to remove some of the water. When the remaining liquid volume is 2 / 3 of the original volume, stop the operation and immediately transfer it to a beaker. Add the sodium sulfachloropyrazine aqueous solution dropwise along the wall of the beaker. After cooling, add the L-menthol solution dropwise to obtain a mixed solution. (3) The mixed solution was placed in a water bath at 30°C to 45°C and subjected to rotary evaporation until no distillate was produced. The precipitate was filtered, dried, and ground to obtain 1.59 g of sodium sulfachloropyrazine-β-cyclodextrin inclusion complex.
[0026] Example 3 Sulfadiazine sodium-β-cyclodextrin inclusion complex formula: Preparation method: (1) dissolving sulfachloropyrazine sodium in an appropriate amount of water to obtain a sulfachloropyrazine sodium aqueous solution, dissolving β-cyclodextrin in an appropriate amount of water to obtain a β-cyclodextrin aqueous solution, and dissolving L-menthol in an appropriate amount of ethanol to obtain an L-menthol solution, and set aside; (2) Place the β-cyclodextrin aqueous solution in a water bath at 35°C to 40°C and heat under reflux to remove some of the water. When the remaining liquid volume is 1 / 2 of the original volume, stop the operation and immediately transfer it to a beaker. Add the sodium sulfachloropyrazine aqueous solution dropwise along the wall of the beaker. After cooling, add the L-menthol solution dropwise to obtain a mixed solution. (3) The mixed solution was placed in a water bath at 30°C to 45°C and subjected to rotary evaporation until no distillate was produced. The precipitate was filtered, dried, and ground to obtain 8.27 g of sodium sulfachloropyrazine-β-cyclodextrin inclusion complex.
[0027] Comparative Example 1 Sulfadiazine sodium-β-cyclodextrin inclusion complex formula: Preparation method: (1) dissolving sulfachloropyrazine sodium in an appropriate amount of water to obtain a sulfachloropyrazine sodium aqueous solution, and dissolving β-cyclodextrin in an appropriate amount of water to obtain a β-cyclodextrin aqueous solution, and setting aside; (2) Place the β-cyclodextrin aqueous solution in a water bath at 35°C to 40°C and heat under reflux to remove some of the water. When the remaining liquid volume is 1 / 2 of the original volume, stop the operation and immediately transfer it to a beaker. Add the sodium sulfachloropyrazine aqueous solution dropwise along the wall of the beaker and cool it to obtain a mixed solution. (3) The mixed solution was placed in a water bath at 30°C to 45°C and subjected to rotary evaporation until no distillate was produced. The precipitate was filtered, dried, and ground to obtain 2.16 g of sodium sulfachloropyrazine-β-cyclodextrin inclusion complex.
[0028] Comparative Example 2 Sulfadiazine Sodium-β-Cyclodextrin Inclusion Complex formula: Preparation method: (1) dissolving sulfachloropyrazine sodium in an appropriate amount of water to obtain a sulfachloropyrazine sodium aqueous solution, dissolving β-cyclodextrin in an appropriate amount of water to obtain a β-cyclodextrin aqueous solution, and dissolving L-menthol in an appropriate amount of ethanol to obtain an L-menthol solution, and set aside; (2) Place the β-cyclodextrin aqueous solution in a water bath at 35°C to 40°C and heat under reflux to remove some of the water. When the remaining liquid volume is 1 / 2 of the original volume, stop the operation and immediately transfer it to a beaker. Add the sodium sulfachloropyrazine aqueous solution dropwise along the wall of the beaker. After cooling, add the L-menthol solution dropwise to obtain a mixed solution. (3) The mixed solution was placed in a water bath at 30°C to 45°C and subjected to rotary evaporation until no distillate was produced. The precipitate was filtered, dried, and ground to obtain 4.36 g of sodium sulfachloropyrazine-β-cyclodextrin inclusion complex.
[0029] Comparative Example 3 Sulfadiazine Sodium-β-Cyclodextrin Inclusion Complex formula: Preparation method: (1) dissolving sulfachloropyrazine sodium in an appropriate amount of water to obtain a sulfachloropyrazine sodium aqueous solution, dissolving β-cyclodextrin in an appropriate amount of water to obtain a β-cyclodextrin aqueous solution, and dissolving L-menthol in an appropriate amount of ethanol to obtain an L-menthol solution, and set aside; (2) adding the sodium sulfachloropyrazine aqueous solution dropwise into the β-cyclodextrin aqueous solution along the wall of the beaker, and then adding the L-menthol solution dropwise to obtain a mixed solution; (3) The mixed solution was placed in a water bath at 30°C to 45°C and subjected to rotary evaporation until no distillate was produced. The precipitate was filtered, dried, and ground to obtain 3.04 g of sodium sulfachloropyrazine-β-cyclodextrin inclusion complex.
[0030] Comparative Example 4 Sulfadiazine Sodium-β-Cyclodextrin Inclusion Complex formula: Preparation method: (1) dissolving sulfachloropyrazine sodium in an appropriate amount of water to obtain a sulfachloropyrazine sodium aqueous solution, dissolving β-cyclodextrin in an appropriate amount of water to obtain a β-cyclodextrin aqueous solution, and dissolving L-menthol in an appropriate amount of ethanol to obtain an L-menthol solution, and set aside; (2) Place the β-cyclodextrin aqueous solution in a water bath at 35°C to 40°C and heat it under reflux to remove some of the water. When the remaining liquid volume is 1 / 2 of the original volume, stop the operation and immediately transfer it to a beaker. Add the sodium sulfachloropyrazine aqueous solution dropwise along the wall of the beaker. Add the L-menthol solution dropwise while the temperature is still hot to obtain a mixed solution. (3) The mixed solution was placed in a water bath at 30°C to 45°C and subjected to rotary evaporation until no distillate was produced. The precipitate was filtered, dried, and ground to obtain 3.51 g of sodium sulfachloropyrazine-β-cyclodextrin inclusion complex.
[0031] Stability verification of sulfachloropyrazine sodium-β-cyclodextrin inclusion complex The sodium sulfachloropyrazine-β-cyclodextrin inclusion complexes of Examples 1 to 3 and the sodium sulfachloropyrazine-β-cyclodextrin inclusion complexes of Comparative Examples 1 to 4 were subjected to an accelerated test at a temperature of 40°C ± 2°C, a relative humidity of 75% ± 5%, and an illumination of 4500 lx ± 500 lx. Samples were taken on the first day, at the end of the second month, at the end of the third month, and at the end of the sixth month, and the sodium sulfachloropyrazine content was determined by high performance liquid chromatography.
[0032] Figure 3 The content change of sodium sulfachloropyrazine in the accelerated test of sodium sulfachloropyrazine-β-cyclodextrin inclusion complexes of Examples 1 to 3 and Comparative Examples 1 to 4 is shown. It can be seen that the present invention overcomes the defect that sodium sulfachloropyrazine is unstable when exposed to light, high temperature and high humidity, and a stable sodium sulfachloropyrazine-β-cyclodextrin inclusion complex is synthesized by using the inclusion complex technology.
[0033] Example 4 A soluble powder for treating avian coccidiosis and its preparation method Take the sodium sulfachloropyrazine-β-cyclodextrin inclusion complex (containing 33.3 g of sodium sulfachloropyrazine) of Example 1, add 5 g of aspartame, 5 g of magnesium stearate, 0.5 g of potassium sorbate, and add glucose to 100 g, mix well, and obtain a soluble powder.
[0034] Example 5 A soluble powder for treating avian coccidiosis and its preparation method Take the sodium sulfachloropyrazine-β-cyclodextrin inclusion complex of Example 2 (containing 33.3 g of sodium sulfachloropyrazine), add 10 g of fructose, 8 g of talcum powder, 0.2 g of sodium benzoate, add lactose to 100 g, mix well, and obtain soluble powder.
[0035] Example 6 A soluble powder for treating avian coccidiosis and its preparation method Take the sodium sulfachloropyrazine-β-cyclodextrin inclusion complex of Example 3 (containing 33.3 g of sodium sulfachloropyrazine), add 2 g of sucralose, 10 g of silicon dioxide, 0.5 g of sodium thiosulfate, add mannitol to 100 g, mix well, and obtain soluble powder.
[0036] Pharmacodynamics experiments Coccidiosis infection occurred in a breeding area of Yuling broiler farm in Luozhuang District, Linyi City. A large number of chickens showed clinical symptoms such as diarrhea, poor appetite, listlessness, and weight loss, and were diagnosed with coccidiosis.
[0037] 120 chickens with coccidiosis with similar symptoms were selected and randomly divided into 4 groups, 30 in each group, for drug administration test treatment. Example 4 group: 1g of Example 4 soluble powder per 1L of water, used for 5 consecutive days. Example 5 group: 1g of Example 5 soluble powder per 1L of water, used for 5 consecutive days. Example 6 group: 1g of Example 6 soluble powder per 1L of water, used for 5 consecutive days. Commercially available group: Commercially available sulfachloropyrazine sodium soluble powder (approval number: veterinary drug word 150281628) per 1L of water, 1g, used for 5 consecutive days. Control group: equal dose of normal saline gavage, used for 5 consecutive days.
[0038] Clinical symptoms: After administration, the broiler chickens in Example 4, Example 5, Example 6 and the commercially available group all showed significant improvement.
[0039] Table 1 Clinical efficacy of soluble powders in relevant examples It is shown that the soluble powder of the present invention has good curative effect in treating chicken coccidiosis.
Claims
1. A soluble powder for treating avian coccidiosis, characterized in that: The soluble powder is composed of 1-3 parts by weight of sulfachloropyrazine sodium, 1-8 parts by weight of beta-cyclodextrin, 0.2-0.8 parts by weight of L-menthol, and pharmaceutically acceptable excipients.
2. The soluble powder according to claim 1, characterized in that The pharmaceutically acceptable excipients are selected from one or more of fillers, flavoring agents, lubricants, preservatives, and antioxidants.
3. The soluble powder according to claim 2, characterized in that The filler is selected from one or more of mannitol, microcrystalline cellulose, glucose and lactose.
4. The soluble powder according to claim 2, characterized in that The flavoring agent is selected from one or more of fructose, aspartame, glucose and sucralose.
5. The soluble powder according to claim 2, characterized in that The lubricant is selected from one or more of silicon dioxide, talc, and magnesium stearate.
6. The soluble powder according to claim 2, characterized in that The preservative is selected from one or more of sodium benzoate, parabens, and potassium sorbate.
7. The soluble powder according to claim 2, characterized in that The antioxidant is selected from one or more of sodium thiosulfate, sodium pyrosulfite and ascorbic acid.
8. A method for preparing the soluble powder according to claim 1, characterized in that: The method comprises the following steps: (1) dissolving sodium sulfachloropyrazine in an appropriate amount of water to obtain a sodium sulfachloropyrazine aqueous solution, dissolving β-cyclodextrin in an appropriate amount of water to obtain a β-cyclodextrin aqueous solution, and dissolving L-menthol in an appropriate amount of an organic solvent to obtain an L-menthol solution, and setting aside; (2) Place the β-cyclodextrin aqueous solution in a water bath at 35°C to 40°C and heat under reflux to remove some of the water. When the remaining liquid volume is 2 / 3 to 1 / 2 of the original volume, stop the operation and immediately transfer the solution to a beaker. Add the sodium sulfachloropyrazine aqueous solution dropwise along the wall of the beaker. After cooling, add the L-menthol solution dropwise to obtain a mixed solution. (3) placing the mixed solution in a water bath at 30°C to 45°C and performing rotary evaporation until no distillate is produced, filtering the precipitate, drying, and grinding to obtain a sodium sulfachloropyrazine-β-cyclodextrin inclusion complex; (4) Mixing the sodium sulfachloropyrazine-β-cyclodextrin inclusion complex with pharmaceutically acceptable excipients to obtain a soluble powder containing sodium sulfachloropyrazine.
9. The method according to claim 8, characterized in that The organic solvent is ethanol.
Citation Information
Cited By
Soluble powder and application thereof in treating avian coccidiosis
CN122075506A
